Biotech

All Articles

OS Treatments refiles $6M IPO to cash HER2 drug, preclinical ADCs

.OS Therapies will definitely note on the NYSE American sell swap today via a $6.4 thousand IPO that...

ALX's waning CD47 feedback cost sends supply spiraling down

.ALX Oncology's phase 2 stomach cancer cells reaction cost has diminished. After seeing its own CD47...

Ionis centers eye disease coming from aim ats of Roche-partnered prospect after information disappoint

.One More of Ionis Pharmaceuticals' essential midphase readouts has disappointed expectations, urgin...

Biogen's chief executive officer pointed out no dangerous handle 2023. He prepares to be bold

.While Biogen's pharma peers are actually looking for late-stage resources along with little danger,...

Instil refills pipe in $2B biobucks handle ImmunOnco

.Instil Biography has actually been a biotech looking for a pipe after it junked its own lead posses...

Biogen walks away from Denali Alzheimer's collab

.Biogen has actually handed back liberties to a very early Alzheimer's health condition plan to Dena...

Takeda water faucets brand new mind of US oncology service-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of considerable management hirings, shootings an...

Vertex, hammered by AATD once more, loses 2 properties on discard stack

.Tip's try to deal with an uncommon hereditary health condition has actually hit yet another misfort...

Vir gains 3 T-cell engagers coming from Sanofi, gives up 25% of personnel

.Vir Medical's second-quarter earnings document had not been short of large headlines. The business ...

Galapagos pauses CAR-T tissue treatment litigation over Parkinsonism instance

.Galapagos has stopped registration in a test of a BCMA-directed CAR-T tissue treatment, pushing the...